Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 20 of 20
2021-06-14 [p.1099]
Q-666 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the government's use of Switch Health for post-arrival coronavirus tests for travellers: (a) what are the service standards in terms of distributing, picking up, and processing tests; (b) what are the service standards for responding to client inquiries or complaints; (c) in what percentage of cases did Switch Health meet or exceed service standards; (d) for cases where standards were not met, what was the reason given; (e) how many of the required post-arrival tests were never completed; (f) of the tests in (e), what is the breakdown by reason (Switch Health unable to provide service in Spanish, traveler refusal, etc.); (g) was there a competitive bid process for the contract awarded to Switch Health and, if so, who were the other bidders; and (h) what are the details of all meetings, including telephone or virtual, that Switch Health had with the government prior to the awarding of the contract, including the (i) date, (ii) names and titles of representatives from Switch Health, (iii) names and titles of government representatives, including any ministerial staff? — Sessional Paper No. 8555-432-666.
2021-05-05 [p.896]
— by Ms. Rempel Garner (Calgary Nose Hill), one concerning health (No. 432-00910);
2021-04-26 [p.827]
Q-513 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the National Advisory Committee on Immunization (NACI) and Health Canada respectively: (a) what scientific evidence, expert opinions, and other factors went into the decision to extend the dosing schedule up to four months between doses of the COVID-19 vaccines; and (b) what is the summary of the minutes of each meeting the NACI had in which dosing timelines were discussed? — Sessional Paper No. 8555-432-513.
2021-04-26 [p.828]
Q-514 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the Public Health Agency of Canada (PHAC): (a) how many doctors and other designated medical professionals have been employed by the agency, broken down by year since 2015; and (b) what percentage of PHAC employees do each of the numbers in (a) represent? — Sessional Paper No. 8555-432-514.
2021-04-14 [p.767]
The notice of motion for the production of papers P-2 was called pursuant to Standing Order 97(1) and was transferred by the clerk to “Notices of Motions (Papers)”.
2021-03-24 [p.683]
Pursuant to order made Monday, January 25, 2021, the House proceeded to the taking of the deferred recorded division on the motion of Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. Cumming (Edmonton Centre), — That, given that,
(i) COVID-19 restrictions have had serious economic and mental health impacts on Canadians,
(ii) COVID-19 restrictions have been advised by the federal government, including specifically by the Prime Minister on three separate occasions in November of 2020, as temporary measures to alleviate pressure on the public healthcare system,
(iii) public health tools, such as rapid tests, shared data on how COVID-19 spreads and vaccines, have not been positioned as permanent solutions to replace COVID-19 restrictions by the federal government, including in areas of federal competency like air travel and border restrictions,
(iv) the President of the United States and the Prime Minister of the United Kingdom have both released public plans for economic reopening, while Canadian officials have not yet given Canadians clarity on when regular economic and social life will be able to resume,
the House call on the government to table within 20 calendar days, following the adoption of this motion, a clear data-driven plan to support safely, gradually and permanently lifting COVID-19 restrictions.
The question was put on the motion and it was negatived on the following division:
(Division No. 77 -- Vote no 77) - View vote details.
YEAS: 122, NAYS: 212
2021-03-23 [p.670]
The order was read for the consideration of the business of supply.
Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. Cumming (Edmonton Centre), moved, — That, given that,
(i) COVID-19 restrictions have had serious economic and mental health impacts on Canadians,
(ii) COVID-19 restrictions have been advised by the federal government, including specifically by the Prime Minister on three separate occasions in November of 2020, as temporary measures to alleviate pressure on the public healthcare system,
(iii) public health tools, such as rapid tests, shared data on how COVID-19 spreads and vaccines, have not been positioned as permanent solutions to replace COVID-19 restrictions by the federal government, including in areas of federal competency like air travel and border restrictions,
(iv) the President of the United States and the Prime Minister of the United Kingdom have both released public plans for economic reopening, while Canadian officials have not yet given Canadians clarity on when regular economic and social life will be able to resume,
the House call on the government to table within 20 calendar days, following the adoption of this motion, a clear data-driven plan to support safely, gradually and permanently lifting COVID-19 restrictions.
Debate arose thereon.
2021-03-23 [p.674]
The House resumed consideration of the motion of Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. Cumming (Edmonton Centre), in relation to the Business of Supply.
The debate continued.
2021-03-23 [p.674]
The question was put on the motion and, pursuant to order made Monday, January 25, 2021, the recorded division was deferred until Wednesday, March 24, 2021, at the expiry of the time provided for Oral Questions.
2021-03-11 [p.635]
— by Ms. Rempel Garner (Calgary Nose Hill), one concerning the democratic process (No. 432-00656);
2021-01-25 [p.446]
Q-292 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the Prime Minister's announcement in May 2020 of an agreement with CanSino Biologics Inc. (CanSinoBIO) in relation to the development of a potential COVID-19 vaccine: (a) what were the original details of the agreement, as understood by the government in May 2020; (b) on what date did the government first become aware that the agreement would not proceed as planned; (c) on what date did the government become aware that shipments of Ad5-nCoV were being blocked by the Chinese government; (d) what reason, if any, did the Chinese government provide to the government for blocking the shipment; (e) has the government transferred any money or any type of expenditures to CanSinoBIO since January 1, 2020, and, if so, what is the total amount sent, broken down by date of transfer; (f) what are the details of any contracts signed with CanSinoBIO since January 1, 2020, including the (i) amount, (ii) original value, (iii) final value, (iv) date the contract was signed, (v) description of goods or services, including volume; (g) was the National Security and Intelligence Advisor to the Prime Minister advised of the terms agreement prior to the Prime Minister's announcement, and, if so, did he approve of the agreement; (h) was the Department of National Defence or the Canadian Security Intelligence Service informed of the details of the agreement prior to the Prime Minister's announcement, and, if so, did they raise any concerns with the Office of the Prime Minister or the Privy Council Office; and (i) what were the results of any security analysis conducted in relation to CanSinoBIO? — Sessional Paper No. 8555-432-292.
2020-11-18 [p.283]
Q-109 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the organization and structure of the Public Health Agency of Canada (PHAC): (a) what was the organizational structure of PHAC, including a breakdown of how many employees or full-time equivalents working in each branch, location and in each position, as of (i) January 1, 2016, (ii) October 1, 2020; and (b) what are the details of the positions that have been eliminated or modified since January 1, 2016, including the (i) previous job title, (ii) new job title, if applicable, (iii) previous job description, (iv) new job description, (v) number of positions impacted, (vi) date the position was eliminated or modified, (vii) number of previous positions eliminated, if applicable? — Sessional Paper No. 8555-432-109.
2020-11-18 [p.284]
Q-110 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to drug products currently awaiting approval and market authorization by Health Canada: (a) what is the complete list of products currently awaiting approval; (b) for each product in (a), what was the (i) date the application was received by the government, (ii) manufacturer, (iii) product name, (iv) summary of product claims, including the list of diseases and conditions the product claims to treat, (v) expected date of decision of approval by Health Canada, if known; and (c) has the time period between the date of application and the decision date by Health Canada, for non-COVID-19 related products increased as a result of reallocating resources during the pandemic, and, if so, what are the specific details, including for which applications and for which products the time period has increased? — Sessional Paper No. 8555-432-110.
2020-10-26 [p.170]
Pursuant to order made Wednesday, September 23, 2020, the House resumed consideration of the motion of Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. O'Toole (Durham), — That the Standing Committee on Health be instructed to undertake a study on the emergency situation facing Canadians in light of the second wave of the COVID-19 pandemic, and that this study evaluate, review and examine any issues relevant to this situation, such as, but not limited to:
(a) rapid and at-home testing approvals and procurement process and schedule, and protocol for distribution;
(b) vaccine development and approvals process, procurement schedules, and protocol for distribution;
(c) federal public health guidelines and the data being used to inform them for greater clarity on efficacy;
(d) current long-term care facility COVID-19 protocols as they pertain solely to federal jurisdiction;
(e) the availability of therapeutics and treatment devices for Canadians diagnosed with COVID-19;
(f) the early warning system, Global Public Health Intelligence Network (GPHIN);
(g) the government’s progress in evaluating pre- and post-arrival rapid testing for travellers;
(h) the availability of paid sick leave for those in need, including quarantine and voluntary isolation;
(i) the adequacy of health transfer payments to the provinces, in light of the COVID-19 crisis;
(j) the impact of the government’s use of World Heath Organization (WHO) advice in early 2020 to delay the closure of borders and delay in the recommendation of wearing of masks on the spread of COVID-19 in Canada;
(k) the Public Health Agency of Canada’s communication strategy regarding COVID-19;
(l) the development, efficacy and use of data related to the government’s COVID Alert application;
(m) Canada’s level of preparedness to respond to another pandemic;
(n) the availability of personal protective equipment (PPE) in Canada and a review of Canada’s emergency stockpile of PPE between 2015 and present;
(o) the government’s contact tracing protocol, including options considered, technology, timelines and resources;
(p) the government’s consideration of and decision not to invoke the federal Emergencies Act;
provided that,
(q) this study begin no later than seven days following the adoption of this motion;
(r) the committee present its findings to the House upon completion and, notwithstanding Standing Order 109, that the government provide a comprehensive response to these findings within 30 days;
(s) evidence and documentation received by the committee during its study of the Canadian response to the outbreak of the coronavirus, commenced during the first session of the 43rd Parliament, be taken into consideration by the committee in the current study;
(t) that each party represented on the committee be entitled to select one witness per one-hour witness panel, and two witnesses per two-hour witness panel;
(u) an order of the House do issue for all memoranda, emails, documents, notes or other records from the Office of the Prime Minister, the Privy Council Office, the office of the Minister of Public Safety and Emergency Preparedness, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada, concerning options, plans and preparations for the GPHIN since January 1, 2018;
(v) an order of the House do issue for a record of all communications between the government and the WHO in respect of options, plans or preparations for any future operation, or absence thereof, of the GPHIN, since January 1, 2018;
(w) an order of the House do issue for all memoranda, emails, documents, notes and other records from the Office of the Prime Minister, the Privy Council Office, the office of the Minister of Public Services and Procurement, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada, concerning plans, preparations, approvals and purchasing of COVID-19 testing products including tests, reagents, swabs, laboratory equipment and other material related to tests and testing applications used in the diagnosis of COVID-19, since March 19, 2020;
(x) an order of the House do issue for all memoranda, emails, documents, notes and other records from the Prime Minister’s Office, the Privy Council Office, the office of the Minister of Public Services and Procurement, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada concerning plans, preparations and purchasing of PPE, including gowns, gloves, masks, respirators, ventilators, visors and face shields, since March 19, 2020;
(y) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the COVID-19 Vaccine Task Force and its subcommittees;
(z) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the Government of Canada’s COVID-19 vaccine distribution and monitoring strategy, including, but not limited to anticipated timelines for the distribution of an approved COVID-19 vaccine across Canada and the prioritization of population groups for vaccination;
(aa) all documents issued pursuant to this order (i) be organized by department and be provided to the Office of the Law Clerk and Parliamentary Counsel within 15 days of the adoption of this order, (ii) be vetted for matters of personal privacy information, and national security, and, with respect to paragraph (y) only, be additionally vetted for information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations between the Government of Canada and a third party, by the Law Clerk and Parliamentary Counsel within seven days of the receipt of the documents, (iii) be laid upon the table by the Speaker, at the next earliest opportunity, once vetted, and permanently referred to the Standing Committee on Health; and
(bb) within seven days after all documents have been tabled pursuant to paragraph (aa), the Minister of Health, the Minister of Public Services and Procurement, the Minister of Public Safety and Emergency Preparedness, and the Minister of Innovation, Science and Industry be ordered to appear separately as witnesses before the Standing Committee on Health, for at least three hours each.
The House proceeded to the taking of the deferred recorded division on the amendment of Mrs. Block (Carlton Trail—Eagle Creek), seconded by Ms. Alleslev (Aurora—Oak Ridges—Richmond Hill), — That the motion be amended by replacing paragraph (aa) with the following:
“(aa) minutes of meetings of the cabinet and its committees be excluded from this order and all documents issued pursuant to this order (i) be organized by department and be provided to the Office of the Law Clerk and Parliamentary Counsel as soon as is practicable in light of the pandemic, but, in any event, not later than November 30, 2020, and, if this is not possible, the Clerk of the Privy Council may request an extension of no more than seven days, by writing a letter to the committee, (ii) be vetted for matters of personal privacy information and national security, and, with respect to paragraph (y) only, be additionally vetted for information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations between the Government of Canada and a third party, by the Law Clerk and Parliamentary Counsel within seven days of the receipt of the documents, (iii) be laid upon the table by the Speaker, at the next earliest opportunity, once vetted, and permanently referred to the Standing Committee on Health; and”.
The question was put on the amendment and it was agreed to on the following division:
(Division No. 12 -- Vote no 12) - View vote details.
YEAS: 175, NAYS: 0
2020-10-26 [p.174]
Pursuant to Standing Order 81(16), the House proceeded to the putting of the question on the main motion, as amended, of Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. O'Toole (Durham), — That the Standing Committee on Health be instructed to undertake a study on the emergency situation facing Canadians in light of the second wave of the COVID-19 pandemic, and that this study evaluate, review and examine any issues relevant to this situation, such as, but not limited to:
(a) rapid and at-home testing approvals and procurement process and schedule, and protocol for distribution;
(b) vaccine development and approvals process, procurement schedules, and protocol for distribution;
(c) federal public health guidelines and the data being used to inform them for greater clarity on efficacy;
(d) current long-term care facility COVID-19 protocols as they pertain solely to federal jurisdiction;
(e) the availability of therapeutics and treatment devices for Canadians diagnosed with COVID-19;
(f) the early warning system, Global Public Health Intelligence Network (GPHIN);
(g) the government’s progress in evaluating pre- and post-arrival rapid testing for travellers;
(h) the availability of paid sick leave for those in need, including quarantine and voluntary isolation;
(i) the adequacy of health transfer payments to the provinces, in light of the COVID-19 crisis;
(j) the impact of the government’s use of World Heath Organization (WHO) advice in early 2020 to delay the closure of borders and delay in the recommendation of wearing of masks on the spread of COVID-19 in Canada;
(k) the Public Health Agency of Canada’s communication strategy regarding COVID-19;
(l) the development, efficacy and use of data related to the government’s COVID Alert application;
(m) Canada’s level of preparedness to respond to another pandemic;
(n) the availability of personal protective equipment (PPE) in Canada and a review of Canada’s emergency stockpile of PPE between 2015 and present;
(o) the government’s contact tracing protocol, including options considered, technology, timelines and resources;
(p) the government’s consideration of and decision not to invoke the federal Emergencies Act;
provided that,
(q) this study begin no later than seven days following the adoption of this motion;
(r) the committee present its findings to the House upon completion and, notwithstanding Standing Order 109, that the government provide a comprehensive response to these findings within 30 days;
(s) evidence and documentation received by the committee during its study of the Canadian response to the outbreak of the coronavirus, commenced during the first session of the 43rd Parliament, be taken into consideration by the committee in the current study;
(t) that each party represented on the committee be entitled to select one witness per one-hour witness panel, and two witnesses per two-hour witness panel;
(u) an order of the House do issue for all memoranda, emails, documents, notes or other records from the Office of the Prime Minister, the Privy Council Office, the office of the Minister of Public Safety and Emergency Preparedness, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada, concerning options, plans and preparations for the GPHIN since January 1, 2018;
(v) an order of the House do issue for a record of all communications between the government and the WHO in respect of options, plans or preparations for any future operation, or absence thereof, of the GPHIN, since January 1, 2018;
(w) an order of the House do issue for all memoranda, emails, documents, notes and other records from the Office of the Prime Minister, the Privy Council Office, the office of the Minister of Public Services and Procurement, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada, concerning plans, preparations, approvals and purchasing of COVID-19 testing products including tests, reagents, swabs, laboratory equipment and other material related to tests and testing applications used in the diagnosis of COVID-19, since March 19, 2020;
(x) an order of the House do issue for all memoranda, emails, documents, notes and other records from the Prime Minister’s Office, the Privy Council Office, the office of the Minister of Public Services and Procurement, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada concerning plans, preparations and purchasing of PPE, including gowns, gloves, masks, respirators, ventilators, visors and face shields, since March 19, 2020;
(y) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the COVID-19 Vaccine Task Force and its subcommittees;
(z) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the Government of Canada’s COVID-19 vaccine distribution and monitoring strategy, including, but not limited to anticipated timelines for the distribution of an approved COVID-19 vaccine across Canada and the prioritization of population groups for vaccination;
(aa) minutes of meetings of the cabinet and its committees be excluded from this order and all documents issued pursuant to this order (i) be organized by department and be provided to the Office of the Law Clerk and Parliamentary Counsel as soon as is practicable in light of the pandemic, but, in any event, not later than November 30, 2020, and, if this is not possible, the Clerk of the Privy Council may request an extension of no more than seven days, by writing a letter to the committee, (ii) be vetted for matters of personal privacy information and national security, and, with respect to paragraph (y) only, be additionally vetted for information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations between the Government of Canada and a third party, by the Law Clerk and Parliamentary Counsel within seven days of the receipt of the documents, (iii) be laid upon the table by the Speaker, at the next earliest opportunity, once vetted, and permanently referred to the Standing Committee on Health; and
(bb) within seven days after all documents have been tabled pursuant to paragraph (aa), the Minister of Health, the Minister of Public Services and Procurement, the Minister of Public Safety and Emergency Preparedness, and the Minister of Innovation, Science and Industry be ordered to appear separately as witnesses before the Standing Committee on Health, for at least three hours each.
2020-10-26 [p.176]
The question was put on the main motion, as amended, and it was agreed to on the following division:
(Division No. 13 -- Vote no 13) - View vote details.
YEAS: 176, NAYS: 152
2020-10-22 [p.161]
The order was read for the consideration of the business of supply.
Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. O'Toole (Durham), moved, — That the Standing Committee on Health be instructed to undertake a study on the emergency situation facing Canadians in light of the second wave of the COVID-19 pandemic, and that this study evaluate, review and examine any issues relevant to this situation, such as, but not limited to:
(a) rapid and at-home testing approvals and procurement process and schedule, and protocol for distribution;
(b) vaccine development and approvals process, procurement schedules, and protocol for distribution;
(c) federal public health guidelines and the data being used to inform them for greater clarity on efficacy;
(d) current long-term care facility COVID-19 protocols as they pertain solely to federal jurisdiction;
(e) the availability of therapeutics and treatment devices for Canadians diagnosed with COVID-19;
(f) the early warning system, Global Public Health Intelligence Network (GPHIN);
(g) the government’s progress in evaluating pre- and post-arrival rapid testing for travellers;
(h) the availability of paid sick leave for those in need, including quarantine and voluntary isolation;
(i) the adequacy of health transfer payments to the provinces, in light of the COVID-19 crisis;
(j) the impact of the government’s use of World Heath Organization (WHO) advice in early 2020 to delay the closure of borders and delay in the recommendation of wearing of masks on the spread of COVID-19 in Canada;
(k) the Public Health Agency of Canada’s communication strategy regarding COVID-19;
(l) the development, efficacy and use of data related to the government’s COVID Alert application;
(m) Canada’s level of preparedness to respond to another pandemic;
(n) the availability of personal protective equipment (PPE) in Canada and a review of Canada’s emergency stockpile of PPE between 2015 and present;
(o) the government’s contact tracing protocol, including options considered, technology, timelines and resources;
(p) the government’s consideration of and decision not to invoke the federal Emergencies Act;
provided that,
(q) this study begin no later than seven days following the adoption of this motion;
(r) the committee present its findings to the House upon completion and, notwithstanding Standing Order 109, that the government provide a comprehensive response to these findings within 30 days;
(s) evidence and documentation received by the committee during its study of the Canadian response to the outbreak of the coronavirus, commenced during the first session of the 43rd Parliament, be taken into consideration by the committee in the current study;
(t) that each party represented on the committee be entitled to select one witness per one-hour witness panel, and two witnesses per two-hour witness panel;
(u) an order of the House do issue for all memoranda, emails, documents, notes or other records from the Office of the Prime Minister, the Privy Council Office, the office of the Minister of Public Safety and Emergency Preparedness, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada, concerning options, plans and preparations for the GPHIN since January 1, 2018;
(v) an order of the House do issue for a record of all communications between the government and the WHO in respect of options, plans or preparations for any future operation, or absence thereof, of the GPHIN, since January 1, 2018;
(w) an order of the House do issue for all memoranda, emails, documents, notes and other records from the Office of the Prime Minister, the Privy Council Office, the office of the Minister of Public Services and Procurement, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada, concerning plans, preparations, approvals and purchasing of COVID-19 testing products including tests, reagents, swabs, laboratory equipment and other material related to tests and testing applications used in the diagnosis of COVID-19, since March 19, 2020;
(x) an order of the House do issue for all memoranda, emails, documents, notes and other records from the Prime Minister’s Office, the Privy Council Office, the office of the Minister of Public Services and Procurement, the office of the Minister of Health, Health Canada and the Public Health Agency of Canada concerning plans, preparations and purchasing of PPE, including gowns, gloves, masks, respirators, ventilators, visors and face shields, since March 19, 2020;
(y) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the COVID-19 Vaccine Task Force and its subcommittees;
(z) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the Government of Canada’s COVID-19 vaccine distribution and monitoring strategy, including, but not limited to anticipated timelines for the distribution of an approved COVID-19 vaccine across Canada and the prioritization of population groups for vaccination;
(aa) all documents issued pursuant to this order (i) be organized by department and be provided to the Office of the Law Clerk and Parliamentary Counsel within 15 days of the adoption of this order, (ii) be vetted for matters of personal privacy information, and national security, and, with respect to paragraph (y) only, be additionally vetted for information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations between the Government of Canada and a third party, by the Law Clerk and Parliamentary Counsel within seven days of the receipt of the documents, (iii) be laid upon the table by the Speaker, at the next earliest opportunity, once vetted, and permanently referred to the Standing Committee on Health; and
(bb) within seven days after all documents have been tabled pursuant to paragraph (aa), the Minister of Health, the Minister of Public Services and Procurement, the Minister of Public Safety and Emergency Preparedness, and the Minister of Innovation, Science and Industry be ordered to appear separately as witnesses before the Standing Committee on Health, for at least three hours each.
Debate arose thereon.
2020-10-22 [p.163]
The House resumed consideration of the motion of Ms. Rempel Garner (Calgary Nose Hill), seconded by Mr. O'Toole (Durham), in relation to the business of supply.
The debate continued.
2020-10-22 [p.163]
Mrs. Block (Carlton Trail—Eagle Creek), seconded by Ms. Alleslev (Aurora—Oak Ridges—Richmond Hill), moved the following amendment, — That the motion be amended by replacing paragraph (aa) with the following:
“(aa) minutes of meetings of the cabinet and its committees be excluded from this order and all documents issued pursuant to this order (i) be organized by department and be provided to the Office of the Law Clerk and Parliamentary Counsel as soon as is practicable in light of the pandemic, but, in any event, not later than November 30, 2020, and, if this is not possible, the Clerk of the Privy Council may request an extension of no more than seven days, by writing a letter to the committee, (ii) be vetted for matters of personal privacy information and national security, and, with respect to paragraph (y) only, be additionally vetted for information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations between the Government of Canada and a third party, by the Law Clerk and Parliamentary Counsel within seven days of the receipt of the documents, (iii) be laid upon the table by the Speaker, at the next earliest opportunity, once vetted, and permanently referred to the Standing Committee on Health; and”.
Debate arose thereon.
2020-10-22 [p.164]
The question was put on the amendment and, pursuant to order made Wednesday, September 23, 2020, the recorded division was deferred until Monday, October 26, 2020, at the expiry of the time provided for Oral Questions.
Results: 1 - 20 of 20

Export As: XML CSV RSS

For more data options, please see Open Data